Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals reported its audited results for FY25 with revenue from operations falling to Rs. 4,331.19 lacs from Rs. 5,042.15 lacs in FY24, a decline of about 14%. Q4 FY25 revenue dropped sharply to Rs. 610.05 lacs versus Rs. 1,197.29 lacs in Q4 FY24. The company swung to a wider net loss of Rs. 2,693.93 lacs versus Rs. 1,972.84 lacs in the prior year, with EPS at Rs. (12.49) versus Rs. (9.15). Total expenses of Rs. 7,094.48 lacs far exceeded total income of Rs. 4,402.08 lacs, pushing operating performance deeper into the red. Net worth turned more negative at Rs. (14,623.89) lacs, debt-equity ratio stood at (1.45), DSCR at (0.07), and operating cash flow turned negative at Rs. (789.10) lacs versus a positive Rs. 236.49 lacs last year. Statutory auditor Bhayani & Co. issued an unmodified (clean) opinion on the results.
Negative for shareholders — widening losses, declining revenue, deeply negative net worth, and negative operating cash flow signal serious financial stress. Despite an unmodified audit opinion, the company's liabilities far exceed assets, raising material solvency and going-concern concerns that are likely to weigh on the stock.